Keith Heinzerling, MD
Addiction Medicine · Santa Monica, CANPI 1184724932
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,050 of the $4,241 with a category attached, or 71.9%. Alkermes, Inc. accounts for 85.6% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $3,631 and has fallen 99.1% since, to $34 in 2025. Among addiction medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 34 payments — averaging $124.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$4K
- Indivior Inc.$134
- Takeda Pharmaceuticals U.S.A., Inc.$68
- AstraZeneca$64
- Idorsia Pharmaceuticals US Inc$51
- Merz Pharmaceuticals, LLC$49
- plus $244 from 7 others
What the payments were for
- Consulting fees$3,05072%
- Travel & lodging$2977%
- Food & beverage$89421%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 8 | $3,630 |
| Indivior Inc. | 5 | $134 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $68 |
| AstraZeneca | 2 | $64 |
| Idorsia Pharmaceuticals US Inc | 3 | $51 |
| Merz Pharmaceuticals, LLC | 2 | $49 |
| Johnson & Johnson | 1 | $49 |
| Amneal Pharmaceuticals LLC | 2 | $45 |
| Lilly USA, LLC | 2 | $41 |
| Omniscient Neurotechnology America Ltd | 1 | $35 |
| CSL Behring | 2 | $32 |
| Biogen | 1 | $26 |
| Acorda Therapeutics, Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VIVITROL$3,347
How this compares
$4,241 in reported general payments places this provider in the 90th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 42 | $9,330 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 28 | $1,089 |
| Buprenorphine Hcl | 23 | $700 |
| Clonazepam | 40 | $577 |
| Naltrexone Hcl | 13 | $452 |
| Pregabalin | 12 | $426 |
| Zolpidem Tartrate ErZolpidem Tartrate | 16 | $320 |
| Bupropion XlBupropion Hcl | 16 | $310 |
| Gabapentin | 54 | $291 |
| Ondansetron OdtOndansetron | 21 | $231 |
| Duloxetine Hcl | 13 | $210 |
| Sertraline Hcl | 12 | $204 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $202 |
| Zolpidem Tartrate | 25 | $198 |
| Temazepam | 30 | $189 |
Paid to pharmacies, not to this prescriber.
Other addiction medicine in Santa Monica
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
- Abraham MalkinLos Angeles$12K
- Jonathan ReitmanBeverly Hills$11K
- Caleb LuskSan Pedro$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.